| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 13 Feb 2025 | 6 Feb 2025 |
| BILCARE LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2025 inter alia to consider and approve the Unaudited Financial Results (Standalone & Consolidated) for the Quarter and Nine Months ended 31st December 2024. Board Meeting Outcome for Unaudited Financial Results (Standalone And Consolidated) For The Quarter & Nine Months Ended 31st December 2024 Together With The Limited Review Report Of The Statutory Auditor Thereon. (As Per BSE Announcement Dated on: 13/02/2025) | ||
| Board Meeting | 10 Jan 2025 | 10 Jan 2025 |
| Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Outcome of Board Meeting held on 10 January 2025 Intimation under Regulation 30 (LODR) - Change in Directorate (Revised) (As Per BSE Announcement Dated on 10.01.2025) | ||
| Board Meeting | 2 Dec 2024 | 2 Dec 2024 |
| Dear Sir, Pursuant to Regulation 30 read with Schedule III, Part A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company, at its meeting held on 2nd December, 2024, has approved the subscription to 48,00,000 convertible warrants (Warrants) issued by Caprihans India Limited (Subsidiary). | ||
| Board Meeting | 13 Nov 2024 | 6 Nov 2024 |
| BILCARE LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2024 inter alia to consider and approve the Un-Audited Financial Results for the quarter and half year ended September 30 2024. Enclosed herewith the Unaudited Financial Results (Standalone and Consolidated) for the Quarter and Half Year Ended 30th September 2024, along with Limited Review Report of Statutory Auditor thereon. (As Per Bse Announcement Dated on 13.11.2024) | ||
| Board Meeting | 4 Sep 2024 | 4 Sep 2024 |
| Outcome of Board Meeting | ||
| Board Meeting | 14 Aug 2024 | 8 Aug 2024 |
| Quarterly Results Approval for Unaudited Financial Results (Standalone and Consolidated) for the quarter ended 30th June 2024 and Appointment of Ms. Alka Sagar as an Additional Independent Director. (As Per BSE Announcement dated on 14.08.2024) | ||
| Board Meeting | 10 Jul 2024 | 10 Jul 2024 |
| Outcome of Board Meeting | ||
| Board Meeting | 27 May 2024 | 17 May 2024 |
| BILCARE LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2024 inter alia to consider and approve Board Meeting Intimation for Inter-Alia To Consider And Take On Record The Audited Financial Result (Standalone & Consolidated) For The Quarter And Year Ended 31st March 2024. Submission of Audited Financial Results under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, for the quarter and year ended 31 March 2024. (As Per BSE Announcement dated on 27.05.2024) Submission of Audited Financial Results under Regulation 33 of SEBI (LODR) 2015 for the quarter & year ended 31st March, 2024 Board of Directors has not recommended any dividend for the year ended 31 March 2024. We further inform that during the year, the Company incorporated a wholly owned subsidiary Bilcare Pharma Solutions Limited (As Per BSE Announcement Dated on 28.05.2024) | ||
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
